#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Last 25 years in the diagnosis and treatment of myelodysplastic syndrome


Authors: J. Čermák
Authors‘ workplace: Ústav hematologie a krevní transfuze, Praha
Published in: Transfuze Hematol. dnes,25, 2019, No. 1, p. 108-117.
Category: Review/Educational Papers

Overview

A review on the development of diagnostic and treatment procedures in patients with myelodysplastic syndromes in the course of last 25 years including new prognostic factors and treatment approaches.

Keywords:

diagnosis – myelodysplastic syndromes


Sources

1. Block M, Jacobson LO. Preleukemic acute leukemia. JAMA 1953;152:1018–1029.

2. Rheingold JJ, Kaufman R, Adelson E, Lear A. Smoldering acute leukemia N Engl J Med 1963;268:812–815.

3. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189–199.

4. Jonasova A, Neuwirtova R, Cermak J, et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol 1998;100:304–309.

5. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079–2088.

6. Germing U, Gattermann N, Strupp C, et al. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 2000;24:983–992.

7. Cermák J, Michalova K, Brezinova J, Zemanova Z. A prognostic impact of separation of refractory cytopenia with multilineage dysplasia and 5q- syndrome from refractory anemia in primary myelodysplastic syndrome. Leuk Res 2003;27:221–229.

8. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292–2302.

9. Malcovati L, Della Porta MG, Strupp C, et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica 2011;96:1433–1440.

10. Cermak J, Kacirkova P, Mikulenkova D, Michalova K. Impact of transfusion dependency on survival in patients with early myelodysplastic syndrome without excess of blasts. Leuk Res 2009;33:1469–1474.

11. Ransdorfová Š, Březinová J, Šárová I, et al. Využití interfázní fluorescenční in situ hybridizace pro analýzu CD34+ buněk v periferní krvi u nemocných s myelodysplastickými syndromy. Transfuze Hematol dnes 2016;21:90–96.

12.
Rigolin GM, Bigoni R, Milani R, et al. Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype. Leukemia 2001;15:1841–1847.

13. Tiu RV, Gondek LP, O’Keefe CL, et al. Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Blood 2011;117:4552–4560.

14. Westers TM, Ireland R, Kern W, et al. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia 2012;26:1730–1741.

15. Degg HJ, Guardiola P. Allogeneic hemopoietic stem cell transplantation in patient with myelodysplastic syndrome or myelofibrosis. Int J Hematol 2002;76(suppl.2):29–34.

16. Cermak J, Vitek A, Mikulenkova D, et al. An analysis of real life data obtained from 30 years follow-up of primary myelodysplastic syndromes (MDS) patients confirms a leading role of stem cell transplantation (SCT) for achievement of prolonged survival. Blood 2018;132:4372.

17. Molldrem JJ, Caples M, Mavroudis D, et al. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 1997;99:699–705.

18. Hellström-Lindberg E, Gulbrandsen N, Lindberg G, et al. Scandinavian MDS Group. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin+granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003;120(6):1037–1046.

19. List AF, Baer MR, Steensma DP, et al. Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. J Clin Oncol 2012;30:2134–2139.

20. Cermak J, Jonasova A, Vondrakova J, et al. A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes. Leuk Res 2013;37:1612–1615.

21. Martino R, Iacobelli S, Brand R, et al. Myelodysplastic Syndrome subcom-
mittee of the Chronic Leukemia Working Party of the European Blood and Marrow Transplantation Group. Retrospective comparison of reducedintensity highdose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006;108:836–846.

22. Fenaux P, Giagounidis A, Selleslag D, et al. MDS-004 Lenalidomide del5q Study Group. A randomized phase 3 study of lenalidomideversus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood 2011;118:3765–3776.

23. Neuwirtová R, Jonášová A, Čermák J, et al. Analýza nemocných s myelodysplastickým syndromem (MDS) s delecí dlouhého ramene 5.chomozomu (del5q)), sledovaných Českou MDS pracovní skupinou: význam pro diagnostické zařazení a určení prognózy. Transfuze Hematol dnes 2009;15:204–209.

24. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223–232.

25. Jonášová A, Čermák J, Červínek L, et al. První zkušenosti České MDS skupiny s terapií 5-azacytidinem u nemocných s myelodysplastickým syndromem s vyšším rizikem (IPSS střední 2 a vysoké riziko), akutní myeloidní leukémií do 30 % myeloblastů a chronickou myelomonocytární leukémií II. Transfuze Hematol dnes 2013;19:125–133.

26. Platzbecker U, Germing U, Götze KS, et al. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. Lancet Oncol 2017;10:1338–1347.

27. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012;120:2454–2465.

28. Malcovati L, Hellström-Lindberg E, Bowen D, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 2013;122:2943–2964.

29. Čermák J, Jonášová A. Myelodysplastický syndrom. Transfuze Hematol dnes 2010;16:42–46.

30. Bejar R, Stevenson KE, Caughey BA, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2012;30:3376–3382.

31. Bejar R, Levinw R, Ebert BE. Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol 2011;29:504–515.

32. Malcovati L, Galli A, Travaglino E, et al. Clinical significance of somatic mutation in unexplained blood cytopenia. Blood 2017;129:3371–3378.

33. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision of the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127:2391–2405.

34. Bejar R. Implications of molecular genetic diversity in myelodysplastic syndromes. Curr Opin Hematol 2017;24:73–78.

Labels
Haematology Internal medicine Clinical oncology

Article was published in

Transfusion and Haematology Today

Issue 1

2019 Issue 1

Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#